XSHE
003017
Market cap330mUSD
Oct 09, Last price
22.68CNY
1D
-0.44%
1Q
1.48%
IPO
-50.36%
Name
Zhejiang Dayang Biotech Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Dayang Biology Technology Co.,Ltd. is a diversified enterprise specializing in the research, development, manufacturing, and global distribution of biological products, agricultural chemicals, and a broad spectrum of chemical compounds. Its extensive product portfolio includes a range of fundamental inorganic chemicals such as potassium carbonate (available in both general and food additive grades) and potassium bicarbonate (also offered as a food additive). They also supply ammonium chloride, catering to both agricultural and industrial needs. Beyond these, the company produces more specialized chemical derivatives, including 2-chloro-6-fluorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and various anisole-based products. Furthermore, Zhejiang Dayang is a supplier of veterinary active pharmaceutical ingredients (APIs), exemplified by amprolium HCL, and manufactures veterinary drug premixes, such as enramycin premixes. Established in 1976, the company maintains its headquarters in Jiande, China.
Key people
Xianyu Wang
Vice Chairman of the Board, Executive Deputy General Manager · since 2021
Xujun Chen
Chief Financial Officer, General Manager, Director · since 2024
Jiangfeng Bao
Deputy General Manager · since 2024
Weijun Guan
Deputy General Manager, Director · since 2009
Yongsheng Qiu
Deputy General Manager, Director · since 2009
Jianfei Ye
Deputy General Manager · since 2021
Yanggui Chen
Chairman, Executive Director · since 2025
Xuping Xu
Secretary of the Board · since 2009
Guoping Wang
Director · since 2024
Qiuyan Han
Independent Director · since 2021
Independent Director · since 2021
Aimin Zeng
Independent Director · since 2021
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||